Avience Biomedicals Shares List at Nearly Double IPO Price on NSE SME Debut
Avience Biomedicals, a medical diagnostics company established in 2019-2024, made a strong debut on the NSE SME platform with shares listing at a 90-99.5% premium over its Rs 208 IPO price. The IPO, fully subscribed multiple times across investor categories, raised Rs 30.24 crore to partly fund a new manufacturing facility in Uttar Pradesh and support working capital. The stock traded actively, reaching an upper price limit shortly after listing.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (69/100). Lens Score 28/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- businessstandard— balanced framing, positive sentiment
- mint— balanced framing, positive sentiment
- economictimes— balanced framing, positive sentiment
- moneycontrol— balanced framing, neutral sentiment
AI Analysis
The article group presents a primarily financial and market-focused perspective without political framing. Coverage centers on investor participation, subscription rates, and company plans, reflecting business and economic viewpoints. There is no evident political bias, as the sources emphasize factual market data and company information rather than political implications or commentary.
The overall sentiment across the articles is positive, highlighting strong investor demand, significant premium listing, and successful IPO subscription. The tone is optimistic about the company's market debut and future prospects, with no critical or negative assessments present. The coverage focuses on factual reporting of market performance and company plans, maintaining an upbeat but neutral tone.
How 4 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.